$2.4 Billion Pharmaceutical Settlement

December 1, 2017

The firm was part of the litigation team that assisted in resolving the claims of approximately 10,000 Actos® users who claimed to have been injured by the drug. Designed and prescribed to help type-2 diabetics control their blood sugar, patients utilizing Actos were diagnosed with bladder cancer at a high rate. After several verdicts in favor of various Plaintiffs, Takeda Pharmaceuticals and its affiliated businesses was driven to enter into a settlement with 10,000 users of this diabetes medication, a number of whom the Napoli Shkolnik legal group was representing. Consequently, Takeda agreed to a $2.4 billion dollar settlement to resolve these cases
Dupixent Cancer Risk: What Patients Need to Know About CTCL

Emerging Research Raises Questions About Dupixent’s Safety Profile  Dupixent (dupilumab) has become one of the most widely prescribed biologic medications for chronic inflammatory conditions, helping over one million patients...

Read the Article
Talcum Powder and Ovarian Cancer Risk: What Consumers Need to Know Now 

In recent years, talcum powder has moved from a household staple to the center of widespread litigation and scientific scrutiny. A growing body of research and high-profile jury verdicts has...

Read the Article
Depo-Provera: What Women Should Know About the Birth Control Shot and Meningioma Risk

Depo-Provera has been widely used for decades as a convenient form of birth control. Administered as an injection every three months, the contraceptive shot offers a highly effective...

Read the Article
Contact Us:
Get a Free Case Evaluation Attorney Referral

Our Locations

Please Contact Us for an In-Person Appointment